^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Hepatocellular Cancer
    Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/21/2021
    Excerpt:
    Hepatocellular carcinoma:...useful in certain circumstances...Dostarlimab-gxly for MSI-H/dMMR tumors